Published in J Biol Chem on June 05, 1998
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Osteoporosis: now and the future. Lancet (2011) 5.81
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol (2000) 1.80
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med (2000) 1.77
Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res (2007) 1.67
TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2002) 1.61
Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest (2004) 1.52
TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout mice. J Mol Med (Berl) (2012) 1.52
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest (2001) 1.45
Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int (2006) 1.42
Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe (2013) 1.41
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol (2008) 1.25
Retracted Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem (2010) 1.24
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20
TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm (2010) 1.20
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther (2007) 1.14
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res (2007) 1.14
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol (2006) 1.14
Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol (2010) 1.12
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Mechanisms balancing skeletal matrix synthesis and degradation. Biochem J (2002) 1.12
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Molecular mechanisms of neonatal brain injury. Neurol Res Int (2012) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol (2011) 1.07
Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors. BMC Cell Biol (2008) 1.05
Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood (2009) 1.05
Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol (2012) 1.05
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure (2012) 1.04
The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell (2004) 1.03
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) (2009) 1.03
Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol (2007) 1.03
EphA2 activation promotes the endothelial cell inflammatory response: a potential role in atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 1.02
Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res (2011) 1.02
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation. J Biol Chem (2014) 1.02
Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol (2004) 1.00
Staphylococcus aureus - induced tumor necrosis factor - related apoptosis - inducing ligand expression mediates apoptosis and caspase-8 activation in infected osteoblasts. BMC Microbiol (2003) 1.00
Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol (2002) 0.99
The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol (2002) 0.98
Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci U S A (2001) 0.98
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 0.97
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag (2012) 0.97
Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis (1999) 0.96
Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. J Biol Chem (2009) 0.96
Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther (2009) 0.96
Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch (2003) 0.96
Regulation of bone turnover by sex steroids in men. J Bone Miner Res (2008) 0.95
Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med (2012) 0.95
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer (2003) 0.95
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal (2010) 0.94
TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol (2006) 0.94
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92
Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther (2009) 0.92
TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis (2011) 0.91
Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res (2012) 0.91
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis (2000) 0.91
Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol Cell Proteomics (2010) 0.90
TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. PLoS One (2012) 0.90
Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol (2003) 0.89
Therapeutic implications of osteoprotegerin. Cancer Cell Int (2009) 0.89
The TRAIL to viral pathogenesis: the good, the bad and the ugly. Curr Mol Med (2009) 0.89
Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene (2015) 0.88
MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer (2014) 0.88
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer (2011) 0.88
siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption. Pharm Res (2010) 0.88
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. Cardiovasc Diabetol (2011) 0.88
DAPK2 is a novel modulator of TRAIL-induced apoptosis. Cell Death Differ (2014) 0.88
Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci U S A (2007) 0.87
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. J Virol (2003) 0.87
Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus (2013) 0.86
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. J Mol Med (Berl) (2008) 0.86
Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score. J Dev Orig Health Dis (2011) 0.86
Staphylococcus aureus and Salmonella enterica serovar Dublin induce tumor necrosis factor-related apoptosis-inducing ligand expression by normal mouse and human osteoblasts. Infect Immun (2001) 0.86
Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem (2009) 0.86
Mediators of inflammation-induced bone damage in arthritis and their control by herbal products. Evid Based Complement Alternat Med (2013) 0.85
Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res (2013) 0.85
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol (2010) 0.85
RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis (2010) 0.85
Regulatory sequences involved in the promotion and termination of RNA transcription. Annu Rev Genet (1979) 54.83
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1995) 11.89
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
A system to study promoter and terminator signals recognized by Escherichia coli RNA polymerase. Gene Amplif Anal (1981) 8.21
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science (2001) 5.40
The relationship between function and DNA sequence in an intercistronic regulatory region in phage lambda. Nature (1978) 5.38
Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. Nat Genet (1995) 5.02
Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature (1990) 4.81
Polymersomes: tough vesicles made from diblock copolymers. Science (1999) 4.76
The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature (1984) 4.61
Purified lambda regulatory protein cII positively activates promoters for lysogenic development. Nature (1981) 4.60
Termination of transcription in E. coli. Cell (1983) 4.42
Efficient expression of Escherichia coli galactokinase gene in mammalian cells. Proc Natl Acad Sci U S A (1982) 4.25
Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem (1992) 4.22
Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med (1977) 4.14
Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure. Nature (1979) 4.11
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
The use of pKc30 and its derivatives for controlled expression of genes. Methods Enzymol (1983) 3.90
Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell (1984) 3.81
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Termination of transcription in bacteriophage lambda. Heterogeneous, 3'-terminal oligo-adenylate additions and the effects of rho factor. J Biol Chem (1975) 3.71
Identification of the residues in human CD4 critical for the binding of HIV. Cell (1989) 3.71
Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med (1998) 3.62
Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology (1996) 3.60
Surveillance and prevention of residential-fire injuries. N Engl J Med (1996) 3.60
Translational coupling at an intercistronic boundary of the Escherichia coli galactose operon. Cell (1982) 3.56
Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci U S A (1989) 3.55
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol Microbiol (2000) 3.50
Induction of Bradyrhizobium japonicum common nod genes by isoflavones isolated from Glycine max. Proc Natl Acad Sci U S A (1987) 3.41
Preparation of tubulin from brain. Methods Enzymol (1982) 3.39
The stabilization of proteins by sucrose. J Biol Chem (1981) 3.34
Highly reiterated sequences of SIMIANSIMIANSIMIANSIMIANSIMIAN. Science (1978) 3.29
Expression and characterization of the human c-myc DNA-binding protein. Mol Cell Biol (1985) 3.24
Constitutive function of a positively regulated promoter reveals new sequences essential for activity. J Biol Chem (1987) 3.23
Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae. Antimicrob Agents Chemother (1977) 3.02
Role of adherence in growth of Acinetobacter calcoaceticus RAG-1 on hexadecane. J Bacteriol (1981) 2.96
Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer (1999) 2.95
Health spending in 1998: signals of change. The Health Accounts Team. Health Aff (Millwood) (2000) 2.92
Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun (1980) 2.91
gridlock, an HLH gene required for assembly of the aorta in zebrafish. Science (2000) 2.90
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
The association of cancer and the nephrotic syndrome. Ann Intern Med (1966) 2.88
Malpractice claims against family physicians are the best doctors sued more? J Fam Pract (1999) 2.87
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Nucleotide sequence homology at the 3' termini of RNA from vesicular stomatitis virus and its defective interfering particles. Proc Natl Acad Sci U S A (1978) 2.82
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Sequence of Cro gene of bacteriophage lambda. Nature (1977) 2.78
Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proc Natl Acad Sci U S A (1984) 2.74
Adherence of Acinetobacter calcoaceticus RAG-1 to human epithelial cells and to hexadecane. Infect Immun (1981) 2.74
Bacterial adherence to polystyrene: a replica method of screening for bacterial hydrophobicity. Appl Environ Microbiol (1981) 2.73
Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet (1997) 2.69
E1A 13S and 12S mRNA products made in Escherichia coli both function as nucleus-localized transcription activators but do not directly bind DNA. Mol Cell Biol (1985) 2.68
The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 2.64
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther (1996) 2.63
Endocytosis in Chang liver cells. Quantitation by sucrose- 3 H uptake and inhibition by cytochalasin B. J Cell Biol (1971) 2.63
The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology (1997) 2.61
Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell (1994) 2.60
A rho-dependent termination site in the gene coding for tyrosine tRNA su3 of Escherichia coli. Nature (1978) 2.58
Affecting gene expression by altering the length and sequence of the 5' leader. Proc Natl Acad Sci U S A (1984) 2.58
Nucleotide sequence of the operator-promoter region of the galactose operon of Escherichia coli. Proc Natl Acad Sci U S A (1977) 2.57
A new nomenclature for IL-1-family genes. Trends Immunol (2001) 2.57
Microinjected c-myc as a competence factor. Science (1985) 2.56
Evolution of two-component signal transduction. Mol Biol Evol (2000) 2.55
Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem (1996) 2.55
Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc Natl Acad Sci U S A (1991) 2.54
Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J Bacteriol (2000) 2.50
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48
Binding sites in Escherichia coli dihydrofolate reductase communicate by modulating the conformational ensemble. Proc Natl Acad Sci U S A (2000) 2.47
Natural occurrence of cross-linked vaccinia virus deoxyribonucleic acid. J Virol (1970) 2.41
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology (1999) 2.40
Use of alternative techniques of hysterectomy in Ohio, 1988-1994. N Engl J Med (1996) 2.40
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol (1993) 2.40
Adenovirus E1a gene product expressed at high levels in Escherichia coli is functional. Science (1984) 2.38
Tumor necrosis factor-alpha expression in ischemic neurons. Stroke (1994) 2.37
Structure and function of the cy control region of bacteriophage lambda. J Mol Biol (1980) 2.37
A promoter of pBR322 activated by cAMP receptor protein. Nucleic Acids Res (1981) 2.37
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem (1996) 2.33
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem (1998) 2.32
Pentapeptide nuclear localization signal in adenovirus E1a. Mol Cell Biol (1987) 2.30
Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun (1991) 2.29
Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun (1998) 2.29
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem (1997) 2.28
Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem (2000) 2.24
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med (1994) 2.23
Promoter for the establishment of repressor synthesis in bacteriophage lambda. Proc Natl Acad Sci U S A (1980) 2.23
Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line. J Immunol (1982) 2.22
Efficient expression of influenza virus NS1 nonstructural proteins in Escherichia coli. Proc Natl Acad Sci U S A (1983) 2.19
A statement on the generalist physician from the American Boards of Family Practice and Internal Medicine. JAMA (1994) 2.16
Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A (2000) 2.16
5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther (1991) 2.14